Aberrant G protein signaling in nervous system tumors

Journal of Neurosurgery

Volumn 97, Issue 3, 2002, Pages 627-642

  Woods, Stacey A ^a   Marmor, Eric ^a   Feldkamp, Matthias ^a   Lau, Nelson ^a   Apicelli, Anthony J ^a   Boss, Gerry ^a   Gutmann, David H ^a   Guha, Abhijit ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Adenoma; Astrocytoma; G protein; Neurofibroma; Neurofibromin; p21 ras; Tuberin; Tuberous sclerosis

Indexed keywords

CELL SURFACE RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; NEUROFIBROMIN;

ADENOMA; ARTICLE; ASTROCYTOMA; CELL DIFFERENTIATION; CELL TRANSFORMATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MEMBRANE BINDING; NERVE SHEATH; NERVOUS SYSTEM TUMOR; NEUROFIBROMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; TUBEROUS SCLEROSIS;

EID: 0036712015     PISSN: 00223085     EISSN: None     Source Type: Journal    
DOI: 10.3171/jns.2002.97.3.0627     Document Type: Article

References (230)

1. Induction of smg p21/rap1A p21/krev-1 p21 gene expression during phorbol ester-induced differentiation of a human megakaryocytic leukemia cell line
2. Clinical and biochemical characteristics of acromegalic patients harboring gsppositive and gsp-negative pituitary tumors
3. Clinically nonfunctioning pituitary tumors are monoclonal in origin
4. Mitogenic and oncogenic properties of the small G protein Rap1b
5. A conserved alternative splice in the von Recklinghausen neurofibromatosis (NF1) gene produces two neurofibromin isoforms, both of which have GTPase-activating protein activity
6. Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines
7. Site and sequence specific DNA methylation in the neurofibromatosis (NF1) gene includes C5839T: The site of the recurrent substitution mutation in exon 31
8. Pituitary adenoma in Olmstead county, Minnesota, 1937-1977. A report of an increasing incidence of diagnosis in women of childbearing age
9. Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1
10. Activating mutations of the Gs alpha gene are associated with low levels of Gs alpha protein in growth hormone-secreting tumors
11. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins
12. ras genes
13. Prognostic and therapeutic consequences of Gs alpha mutations in somatotroph adenomas
14. Impact of gsp oncogene on the expression of genes coding for Gsalpha, Pit-1, Gi2alpha, and somatostatin receptor 2 in human somatotroph adenomas: Involvement in octreotide sensitivity
15. Aberrant regulation of ras proteins in malignant tumor cells from type 1 neurofibromatosis patients
16. Complete human NF1 cDNA sequence: Two alternatively spliced mRNAs and absence of expression in a neuroblastoma line
17. Receptor-to-effector signaling through G proteins: Roles for beta gamma dimers as well as alpha subunits
18. Receptor-effector coupling by G proteins
19. Regulatory mechanisms that modulate signalling by G-protein-coupled receptors
20. All in the family? New insights and questions regarding interconnectivity of Ras, Rap1 and Ral
21. ras oncogenes in human cancer: A review
22. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues
23. Ezrin: A protein requiring conformational activation to link microfilaments to the plasma membrane in the assembly of cell surface structures
24. The small GTPase rab5 functions as a regulatory factor in the early endocytic pathway
25. Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor
26. Pituitary hyperplasia and gigantism in mice caused by a cholera toxin transgene
27. Alteration of G alpha subunits mRNA levels in bromocriptine resistant prolactinomas
28. Increasing complexity of Ras signaling
29. Oncogenes and signal transduction
30. Apparent preferential loss of heterozygosity at TSC2 over TSC1 chromosomal region in tuberous sclerosis hamartomas
31. 9q34 loss of heterozygosity in a tuberous sclerosis astrocytoma suggests a growth suppressor-like activity also for the TSC1 gene
32. Mechanism of adenylate cyclase activation by cholera toxin: Inhibition of GTP hydrolysis at the regulatory site
33. Brain Tumor Statistics: 1990-1994
34. Human Sos1: A guanine nucleotide exchange factor for Ras that binds to GRB2
35. Expression of p21 ras in normal and malignant human tissues: Lack of association with proliferation and malignancy
36. Mouse models of tumor development in neurofibromatosis type 1
37. The G-protein nanomachine
38. New roles for G-protein beta gammadimers in transmembrane signalling
39. A new constitutively activating mutation of the Gs protein alpha subunit-gsp oncogene is found in human pituitary tumors
40. Structures of active conformations of Gi alpha 1 and the mechanism of GTP hydrolysis
41. Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene
42. Linkage of the tuberous sclerosis locus to a DNA polymorphism detected by v-abl
43. The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, Schwann cells, and oligodendrocytes
44. The c-Ha-ras1, insulin and betaglobin loci map outside the deletion associated with aniridiaWilms' tumor
45. Three-dimensional structure of an oncogene protein: Catalytic domain of human cH-ras p21
46. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis
47. Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses
48. JNK1: A protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain
49. Evidence for the in vitro and in vivo interaction of Ras with protein kinase C zeta
50. Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas
51. Ras signalling and apoptosis
52. Regulation of p21ras by GTPase activating proteins and guanine nucleotide exchange proteins
53. Regulatory mechanisms for ras proteins
54. Differential effects of cAMP in neurons and astrocytes. Role of B-raf
55. Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation
56. Toward a survey of somatic mutation of the NF1 gene in benign neurofibromas of patients with neurofibromatosis type 1
57. Dual growth arrest pathways in astrocytes and astrocytic tumors in response to Raf-1 activation
58. Calcium activation of Ras mediated by neuronal exchange factor Ras-GRF
59. Neurofibromatosis type 1 peripheral nerve tumors: Aberrant activation of the Ras pathway
60. Neurofibromatosis type 1: Piecing the puzzle together
61. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens
62. The farnesyltransferase inhibitor L-744, 832 inhibits the growth of astrocytomas through a combination of antiproliferative, antiangiogenic, and proapoptotic activities
63. Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras
64. Isotype-specific Ras. GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status
65. Physical mapping of the von Recklinghausen neurofibromatosis region on chromosome 17
66. Physical mapping of a translocation breakpoint in neurofibromatosis
67. Mutation and polymorphism analysis in the tuberous sclerosis 2 (TSC2) gene
68. Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133
69. A cluster of phosphorylation sites on the cyclic AMP-regulated nuclear factor CREB predicted by its sequence
70. Cortical tuber count: A biomarker indicating neurologic severity of tuberous sclerosis complex
71. Turning off the signal: Mechanisms that attenuate signaling by G protein-coupled receptors
72. Loss of heterozygosity on chromosome 16p13.3 in hamartomas from tuberous sclerosis patients
73. Neurofibromatosis type 1 gene product (neurofibromin) associates with microtubules
74. Ras activation in astrocytomas and neurofibromas
75. Proliferation of human malignant astrocytomas is dependent on Ras activation
76. Ras-GTP levels are elevated in human NF1 peripheral nerve tumors
77. Loss of neurofibromin in adrenal gland tumors from patients with neurofibromatosis type I
78. Expression of two new protein isoforms of the neurofibromatosis type 1 gene product, neurofibromin, in muscle tissues
79. Expression of the neurofibromatosis 1 (NF1) isoforms in developing and adult rat tissues
80. Increased neurofibromatosis 1 gene expression in astrocytic tumors: Positive regulation by p21-ras
81. Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation
82. Alterations in the rap1 signaling pathway are common in human gliomas
83. Expression of the tuberous sclerosis complex gene products, hamartin and tuberin, in central nervous system tissues
84. Developmental regulation of a neuron-specific neurofibromatosis 1 isoform
85. Human N-ras: cDNA cloning and gene structure
86. Identification of transforming gene in two human sarcoma cell lines as a new member of the ras gene family located on chromosome 1
87. Biological activity and separation of a leukaemogenic virus from murine sarcoma virus-Harvey (MSV-H)
88. Loss of heterozygosity in the tuberous sclerosis (TSC2) region of chromosome band 16p13 occurs in sporadic as well as TSC-associated renal angiomyolipomas
89. Clonal origin of pituitary adenomas
90. Neurofibromin GTPase-activating protein-related domains restore normal growth in Nf1-/-cells
91. Activated Ras interacts with the Ral guanine nucleotide dissociation stimulator
92. Molecular model of the G protein alpha subunit based on the crystal structure of the HRAS protein
93. National Institutes of Health consensus conference: Tuberous sclerosis complex
94. There are GAPS and there are GAPS
95. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1
96. Cytogenetic analysis of soft tissue sarcomas. Recurrent chromosome abnormalities in malignant peripheral nerve sheath tumors (MPNST)
97. Suppression of tumorigenicity by the wild-type tuberous sclerosis 2 (Tsc2) gene and its C-terminal region
98. A search for evidence of somatic mutations in the NF1 gene
99. K-ras is an essential gene in the mouse with partial functional overlap with N-ras
100. Gps mutations in Chilean patients harboring growth hormone-secreting pituitary tumors
101. Immunohistochemical evaluation of Leu-7, myelin basic-protein, S100-protein, glialfibrillary acidic-protein, and LN 3 immunoreactivity in nerve sheath tumors and sarcomas
102. Inactivation of the NF1 gene in human melanoma and neuroblastoma cell lines without impaired regulation of GTP.Ras
103. Ras effectors and their role in mitogenesis and oncogenesis
104. RAC regulation of actin polymerization and proliferation by a pathway distinct from Jun kinase
105. Linkage of an important gene locus for tuberous sclerosis to a chromosome 16 marker for polycystic kidney disease
106. Prevalence of Gs alpha mutations in Korean patients with pituitary adenomas
107. Identification and characterization of R-ras3: A novel member of the RAS gene family with a non-ubiquitous pattern of tissue distribution
108. Infective and noninfective viral murine leukemias
109. Allelic loss of the NF1 gene in NF1-associated plexiform neurofibromas
110. A germline insertion in the tuberous sclerosis (Tsc2) gene gives rise to the Eker rat model of dominantly inherited cancer
111. cDNA structure, alternative splicing and exon-intron organization of the predisposing tuberous sclerosis (Tsc2) gene of the Eker rat model
112. Intragenic Tsc2 somatic mutations as Knudson's second hit in spontaneous and chemically induced renal carcinomas in the Eker rat model
113. EGL-10 regulates G protein signaling in the C. elegans nervous system and shares a conserved domain with many mammalian proteins
114. The TSC1 tumor suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho
115. Clinical characteristics of acromegalic patients whose pituitary tumors contain mutant Gs protein
116. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumors
117. Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma
118. Precise localization of NF1 to 17q11.2 by balanced translocation
119. TP53 mutations are frequent in malignant NF1 tumors
120. Differential expression of the ras gene family in mice
121. Malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1: A clinicopathologic and molecular study of 17 patients
122. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
123. Autophosphorylation mutants of the EGF-receptor signal through auxiliary mechanisms involving SH2 domain proteins
124. A new function for a phosphotyrosine phosphatase: Linking GRB2-Sos to a receptor tyrosine kinase
125. Somatic mutations in the neurofibromatosis 1 gene in human tumors
126. Genomic organization of the neurofibromatosis 1 gene (NF1)
127. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumors of glial origin
128. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling
129. Two G protein oncogenes in human endocrine tumors
130. National survey of patterns of care for brain-tumor patients
131. The GAP-related domain of tuberin, the product of the TSC2 gene, is a target for missense mutations in tuberous sclerosis
132. The cytoskeleton and brain tumor cell migration
133. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21
134. Mutations in the GTP-binding site of GS alpha alter stimulation of adenylyl cyclase
135. Novel small GTPase M-Ras participates in reorganization of actin cytoskeleton
136. Ras signaling and NF1
137. Tumors of central neuroepithelial origin
138. Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis
139. p120 Ras GTPase-activating protein interacts with Ras-GTP through specific conserved residues
140. Molecular switch for signal transduction: Structural differences between active and inactive forms of protooncogenic ras proteins
141. Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK
142. Simultaneous loss of hamartin and tuberin from the cerebrum, kidney and heart with tuberous sclerosis
143. Binding of a nuclear protein to the cyclic-AMP response element of the somatostatin gene
144. Regulation of effectors by G-protein alpha and beta gamma-subunits. Recent insights from studies of the phospholipase c-beta isoenzymes
145. Characterization of the cytosolic tuberin-hamartin complex. Tuberin is a cytosolic chaperone for hamartin
146. Rho, rac and cdc42 GTPases: Regulators of actin structures, cell adhesion and motility
147. Two NF1 translocations map within a 600-kilobase segment of 17q11.2
148. In vivo functions of heterotrimeric G-proteins: Studies in Galpha-deficient mice
149. A Drosophila SH2-SH3 adaptor protein implicated in coupling the sevenless tyrosine kinase to an activator of Ras guanine nucleotide exchange, Sos
150. Expression and differential splicing of the mouse TSC2 homolog
151. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene
152. Alternative splicing of exons 29 and 30 in the neurofibromatosis type 1 gene
153. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas
154. The expression of hamartin, the product of the TSC1 gene, in normal human tissues and in TSC1- and TSC2-linked angiomyolipomas
155. Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles
156. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo
157. Growth hormonereleasing hormone stimulates mitogen-activated protein kinase
158. Chromosomal localization of three human ras genes by in situ molecular hybridization
159. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis
160. Two loci for tuberous sclerosis: One on 9q34 and one on 16p13
161. Chromosomal sites of integration of simian virus 40 DNA sequences mapped by in situ hybridization in two transformed hybrid cell lines
162. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects
163. Distinct patterns of actin organization regulated by the small GTP-binding proteins Rac and Rho
164. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors
165. Pigmentation phenotypes of variant extension locus alleles result from point mutations that alter MSH receptor function
166. Homonucleotide tracts, short repeats and CpG/CpNpG motifs are frequent sites for heterogeneous mutations in the neurofibromatosis type 1 (NF1) tumor-suppressor gene
167. Evidence of DNA methylation in the neurofibromatosis type 1 (NF1) gene region of 17q11.2
168. Phosphatidylinositol-3-OH kinase as a direct target of Ras
169. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras
170. The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1
171. Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases
172. Molecular cloning of a GTPase activating protein specific for the Krev-1 protein p21rap1
173. T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB and Harvey-MSV transforming genes
174. Identification of NF1 mutations in both alleles of a dermal neurofibroma
175. GTPase-activating proteins: Helping hands to complement an active site
176. Heterotrimeric G-protein betagamma-dimers in growth and differentiation
177. Confirmation of a double-hit model for the NF1 gene in benign neurofibromas
178. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders
179. A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty
180. Single cell Ras-GTP analysis reveals altered Ras activity in a subpopulation of neurofibroma Schwann cells but not fibroblasts
181. Understanding Ras: 'It ain't over 'til it's over'
182. Three human transforming genes are related to the viral ras oncogenes
183. Clinical, neuropathological and genetic aspects of the tuberous sclerosis complex
184. Diversity of G proteins in signal transduction
185. Requirement for c-ras proteins during viral oncogene transformation
186. GTPase mechanism of Gproteins from the 1.7-a crystal structure of transducin alpha-GDP-AIF-4
187. On the natural history of von Recklinghausen neurofibromatosis
188. Role of the tuberous sclerosis gene-2 product in cell cycle control. Loss of the tuberous sclerosis gene-2 induces quiescent cells to enter S phase
189. Mutations in the alpha subunit of the stimulatory regulatory protein of adenylyl cyclase (Gs) in human GH-secreting pituitary adenomas. Biochemical, clinical, and morphological aspects
190. Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers
191. Somatotroph hypoplasia and dwarfism in transgenic mice expressing a non-phosphorylatable CREB mutant
192. gsp mutations in human thyroid tumors
193. Evidence for the presence of two amino-terminal isoforms of neurofibromin, a gene product responsible for neurofibromatosis type 1
194. Reduced expression of neurofibromin in the soft tissue tumors obtained from patients with neurofibromatosis type I
195. Rho small G protein and cytoskeletal control
196. The role of G proteins in transmembrane signalling
197. Rescue of a Drosophila NF1 mutant phenotype by protein kinase A
198. Structure of ras proteins
199. Structural differences between a ras oncogene protein and the normal protein
200. Activating mutations of the Gs alpha-gene in nonfunctioning pituitary tumors
201. Expression of growth factor receptors in human brain tumours
202. The murine N-ras gene is not essential for growth and development
203. Mutational and functional analysis of the neurofibromatosis type 1 (NF1) gene
204. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas
205. Identification of the tuberous sclerosis gene TSC 1 on chromosome 9q34
206. Type 1 neurofibromatosis gene: Identification of a large transcript disrupted in three NF1 patients
207. Signaling pathways in Ras-mediated tumorigenicity and metastasis
208. Ligand-induced transformation by a noninternalizing epidermal growth factor receptor
209. Multiple Ras functions can contribute to mammalian cell transformation
210. Identification of tuberin, the tuberous sclerosis-2 product. Tuberin possesses specific Rap1GAP activity
211. Expression of the TSC2 product tuberin and its target Rap1 in normal human tissues
212. Tuberous sclerosis complex and subependymal giant cell astrocytoma
213. Novel mutations detected in the TSC2 gene from both sporadic and familial TSC patients
214. Ras-dependent activation of the small GTPase Ral
215. Germline mutations in NF1 patients with malignancies
216. The tuberous sclerosis 2 gene product, tuberin, functions as a Rab5 GTPase activating protein (GAP) in modulating endocytosis
217. The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae
218. Loss of NF1 alleles in phaeochromocytomas from patients with type I neurofibromatosis
219. Phosphorylation-induced binding and transcriptional efficacy of nuclear factor CREB
220. Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors
221. Farnesyltransferase inhibitors block the neurofibromatosis type I(NF1) malignant phenotype
222. Subependymal astrocytic hamartomas in the Eker rat model of tuberous sclerosis
223. Rap1 mediates sustained MAP kinase activation induced by nerve growth factor
224. Microinjection of smg/rap1/Krev-1 p21 into Swiss 3T3 cells induces DNA synthesis and morphological changes
225. Rare mutations of the Gs alpha subunit gene in human endocrine tumors. Mutation detection by polymerase chain reaction-primer-introduced restriction analysis
226. The Aspergillus FlbA RGS domain protein antagonizes G protein signaling to block proliferation and allow development
227. Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain